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Abstract Non-occupational post-exposure prophylaxis
(nPEP) use is an HIV prevention strategy that has been
recommended by the CDC to prevent HIV infection after a
high risk sexual exposure since 1997. In a behavioral
intervention trial of 4,295 MSM we assessed perceptions
and use of nPEP over 4 years in six cities across the United
States. Overall, 1.9% of MSM reported use of nPEP prior
to enrollment, and 6.3% at least once during the trial.
Awareness of nPEP was reported by 47.5%, with higher
awareness in two sites with funded nPEP programs. Three
seroconversions occurred in the 384 visits where nPEP
courses were reported, with no effect of nPEP on risk of
HIV acquisition in this cohort (hazard ratio = 0.91, 95%
conﬁdence interval [0.29, 2.86]). NPEP users were a riskier
group: increased odds of nPEP use were observed in
association with multiple partners and unprotected recep-
tive and insertive anal sex with HIV infected partners and
partners with unknown HIV status. NPEP use was also
associated with use of illicit drugs (injection drugs, crack
cocaine, hallucinogens, and amphetamines). Importantly,
willingness to use nPEP after high risk sex was associated
with lower odds of high risk sex. After an episode of nPEP
use, nPEP users remained more likely to report high risk
sex than those in this cohort who had not previously used
nPEP. However, within the subset of people who had
previously reported high risk sex, previous nPEP use was
not associated with higher odds of high risk sex, thus
allaying fears that availability of nPEP would lead to an
increase in high risk sex.
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Introduction
Non-occupational post-exposure prophylaxis (nPEP) is an
emergency medical response where antiretroviral drugs
are given to prevent HIV infection after high risk sexual
or injection drug use exposure [1–3]. For greatest potential
efﬁcacy, nPEP should be initiated within 2–24 h (and
no later than 48–72 h) of possible exposure to HIV and
must continue for 28 days [2]. Although nPEP has not
been conclusively proven to prevent the acquisition of
HIV infection, human and animal clinical and observa-
tional studies suggest that if medication is initiated quickly
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[2–9].
Studies of occupational post-exposure prophylaxis
(PEP) provide strong support for efﬁcacy in reducing HIV
transmission risk. For example, a multi-site international
case–control study of health care workers exposed to HIV-
infected blood found an 80% reduction in the odds of
infection for those individuals who received PEP [10].
Studies examining use of non-occupational PEP after
sexual assault suggest the treatment might reduce risk of
infection following sexual HIV exposure [11, 12], and a
trial of take home nPEP in Brazilian men who have sex
with men (MSM) reported nPEP users were much less
likely to seroconvert after engaging in risky sexual prac-
tices than those who did not use nPEP [5].
NPEP is not widely utilized after high risk sexual
exposure in the United States. Between 1998 and 2004
the national US nPEP register received approximately 800
nPEP reports; although it is believed that the majority of
clinicians did not report to the registry [3]. Fenway
Community Health, which serves a large proportion of
MSM in the Boston area, prescribes an average of 60
courses of nPEP each year [13]. San Francisco clinics
with nPEP studies reported about 400 nPEP patients in
2.5 years [3]. One multi-site HIV vaccine study found
that only two percent of 5,418 participants (majority
MSM) had reported nPEP use during the study, although
46% had heard of nPEP [14]. Predictors of nPEP use
among trial participants included higher educational level,
greater recreational drug use, study enrollment in Cali-
fornia, and having a known HIV-infected partner. A cross
sectional study of gay and bisexual men in San Francisco
found slightly higher levels of use (4%) but similar levels
of awareness [15].
When nPEP became widely available in the mid-to-late
1990s, clinical and public health communities raised con-
cerns that a perception that nPEP could prevent HIV
infection might increase the level or frequency of high risk
sexual and injection drug behaviors [16]. Some studies
have suggested that nPEP users may be recurrent sexual
risk takers and since HIV seroconversions among nPEP
users have occurred [17, 18], it is known nPEP may only be
partially effective. However, to date no studies have found
that use or awareness of nPEP has led to increase in high-
risk sexual behavior among MSM [5, 17–22].
In this study of nPEP use in a large multi-site longi-
tudinal study of high risk MSM, we examined knowledge
and use of nPEP and its association with HIV risk
behaviors, including risk of HIV seroconversion. We
assessed the impact of nPEP on risk disinhibition before
and after nPEP use and characterized the sexual risk of
nPEP users using assessments of nPEP use over a 4 year
period.
Methods
Participants and Procedures
The EXPLORE study was a randomized HIV-prevention
trial among 4295 MSM conducted in six U.S. cities
between January 1999 and February 2003 [23]. Of the six
cities, San Francisco and Boston had funded nPEP initia-
tives associated with the study site, whereas Seattle, Chi-
cago, New York and Denver did not. Men, 16 years or
older, were eligible to enroll if they were HIV-uninfected
and reported anal sex with another man during the past
year, excluding those in a mutually monogamous rela-
tionship for the past 2 years with an HIV-uninfected male
partner [24]. Men were randomized to receive a behavioral
intervention versus standard risk reduction counseling. The
experimental intervention consisted of 10 core counseling
modules delivered over 6 months in one-on-one counseling
sessions with subsequent maintenance sessions every
3 months [25]. The intervention was designed to address
individual, interpersonal, and situation-related factors
associated with risk taking among men who have sex with
men, such as greater pleasure in or enjoyment of risk-
related sexual behavior, negative mood states, communi-
cation difﬁculties, social norms encouraging mispercep-
tions of risk and risk taking, use of alcohol or recreational
drugs, and life events and environments that are catalysts
for risk taking. The standard risk reduction counseling was
modeled after Project RESPECT [26]. Participants in both
arms were tested for HIV every 6 months and completed a
sexual risk behavior and psychosocial assessment ques-
tionnaire using audio-computer-assisted self-interview
(ACASI). Additional methods for data collection of the
EXPLORE cohort have been described previously [23–25].
Measures
The primary outcome in EXPLORE was HIV serocon-
version: blood samples were collected for HIV at each
6 month follow-up visit over the study’s duration. Anti-
bodies to HIV were detected by ELISA. Serum samples
shown to be reactive after a ﬁrst test were retested in
duplicate. Repeatedly reactive samples were conﬁrmed by
western-blot assay or immunoﬂuorescence.
Knowledge about nPEP, willingness to use nPEP, access
to nPEP, nPEP use and perceptions about disinhibition
were assessed at baseline and each scheduled visit using
ACASI. Knowledge about nPEP was assessed at baseline:
‘‘Have you read or heard about the idea of HIV-negative
people taking anti-HIV medications right before or after a
high-risk exposure, to keep from getting infected with
HIV?’’. Willingness to use nPEP was assessed at each visit
by whether participants were ‘‘very likely,’’ ‘‘somewhat
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123likely,’’ or ‘‘not at all likely,’’ to try anti-HIV medications
to prevent HIV infection after unprotected receptive anal
sex with an HIV-positive partner. NPEP access was
assessed through Yes/No responses to ‘‘If you had a high-
risk exposure and wanted to get anti-HIV medications to
try to prevent HIV infection and cost was not an issue, do
you think you would be able to easily obtain the drugs?’’.
Lifetime NPEP use was assessed at baseline by responses
to ‘‘Have you ever used anti-HIV medications to prevent
HIV infection either before or after a high-risk sexual or
drug use exposure?’’; at follow-up visits, participants
reported any nPEP use since the last visit. Lastly, percep-
tion about nPEP and disinhibition were recorded on a 6
point Likert scale from strongly, somewhat, or slightly
disagree, to slightly, somewhat, or strongly agree with the
statement ‘‘Easy access to PEP will increase unsafe sex
among people I know.’’
Non-prescription drug use in the last 6 months was
coded as any use of each of marijuana, poppers, cocaine,
amphetamines, hallucinogens, and injection drugs. Current
alcohol use was categorized as ‘‘none,’’ ‘‘light,’’ (three or
less drinks/day on no more than 1–2 days/week) ‘‘moder-
ate,’’ (four or ﬁve drinks/day on no more than 1–2 days/
week, or one to ﬁve drinks/day on 3–6 days/week, or one
to three drinks/day on a daily basis) or ‘‘heavy’’ (four or
more drinks every day or six or more drinks on a typical
day when drinking).
High risk HIV sexual behaviors were any unprotected
anal sex in the previous 6 months, categorized by reported
HIV status of partners: HIV-infected (HIV?), unknown
HIV status(HIV-unk) or HIV uninfected (HIV-); and
unprotected receptive(URA) or insertive(UIA) anal sex,
resulting in six sexual risk variables: URA with HIV?, i.e.,
any unprotected receptive anal sex with an HIV-infected
partner; UIA with HIV?; URA with HIV-unk; UIA with
HIV-unk; URA with HIV-; UIA with HIV-. We also
created a composite sexual risk measure, serodiscordant
unprotected anal sex (SDUA), deﬁned as any unprotected
receptive or insertive anal sex with HIV-infected or
unknown HIV status partners.
Statistical Methods
Association of baseline nPEP questions with demographic
characteristics was assessed using Chi-squared tests for site
and race/ethnicity, and test for trend for age and education.
Longitudinal models of nPEP use include only ‘‘on study’’
nPEP use (i.e., use during follow-up), since nPEP use at
baseline reﬂected prior lifetime use. Logistic regression is
used to assess association between nPEP use and sexual
risk and substance use, with generalized estimating equa-
tion (GEE) modeling methods use to account for within
subject correlation of the repeated measure of nPEP. All
models assessing association of nPEP with risk behaviors
or drug and alcohol risk were adjusted for site, study visit,
education and race/ethnicity.
Survival analysis with discrete, twice yearly visits was
used to assess the association between HIV seroconversion
and time dependent use of nPEP, stratiﬁed by site and
adjusted for visit. A paired t-test was used to assess change
in disinhibition perception score before and after nPEP,
where a numeric score was constructed from the 6 point
Likert agreement scale (score 1 = strongly disagree to
6 = strongly agree).
Association between nPEP use at the previous visit,
willingness and the sexual risk behavior outcome SDUA
used logistic regression with GEE methods, adjusting for
site, study visit, education and race/ethnicity. These anal-
yses include only risk behaviors following the 6 month
visit, as on-study nPEP use is ﬁrst reported at 6 months.
Results
Extent of nPEP Use in EXPLORE Participants
Amongst the 4,295 participants in Explore, 315 people
reported using nPEP on at least one occasion, 81 (1.9%)
people reported nPEP use prior to enrollment, 256 people
(6.3%) reported nPEP use during study participation, 44 of
whom reported nPEP use at more than one visit. No associ-
ation between nPEP use and race/ethnicity, age and educa-
tionwasfoundatbaselineorduringfollow-up(Table 1).The
two nPEP sites, Boston and San Francisco, had higher levels
of nPEP use compared to the other 4 sites at baseline (3.6%
vs. 1.0%, v
2 = 31, P\0.001) and during follow-up (2.1%
vs. 1.0% of visits, v
2 = 30, P\0.001).
nPEP Knowledge, Willingness and Access
At baseline, 2,037 participants (47.5%) had heard of nPEP,
with higher awareness reported at nPEP sites (62%) rela-
tive to non-nPEP sites (40%). NPEP sites had more rec-
ognition through advertising (23% vs. 8% at non nPEP
sites) and newspaper (62% vs. 48%); whereas non-nPEP
sites had information came directly from health care pro-
viders (18% in nPEP sites vs. 29% at non nPEP sites).
However there was no difference in willingness to use
nPEP: at nPEP sites 69% of MSM reported at baseline they
were ‘‘very likely’’ to use nPEP after a high risk exposure,
compared to 66% at non-nPEP sites (v
2 = 5.6, P = 0.06).
Perceived access to nPEP was only modestly better in the
nPEP sites of Boston and San Francisco, where 58% of
participants thought they would have ready access to nPEP
compared to 53% at the sites with no nPEP program
(v
2 = 8.7, P = 0.003).
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Use During EXPLORE
More nPEP use occurred in men reporting illicit drug use,
both injected and non-injected (Table 2). Any non-injec-
tion drug use was associated with 50% increase in adjusted
odds ratio (aOR) of nPEP use (aOR: 1.5, 95% conﬁdence
interval (95%CI) [1.1, 1.9]). Increased odds of nPEP were
seen with use of poppers, crack cocaine, amphetamines and
hallucinogens, although not with marijuana or cocaine that
was snorted or sniffed. Men reporting injection drug use
had signiﬁcantly higher odds of reporting nPEP use (aOR:
2.44, [95%CI: 1.69, 3.51]). Alcohol use, reﬂecting drinking
frequency behavior, was not associated with higher odds of
nPEP use.
Association Between HIV Risk and nPEP Use During
Explore
No association was found between risk of HIV serocon-
version and nPEP use. Three seroconversions occurred at
384 visits (1.56 per 100 person years) with nPEP use
compared to 210 seroconversions in the 25,550 visits (1.64
per 100 person years) with no nPEP use (hazard ratio: 0.91,
[95%CI: 0.29, 2.86]).
NPEPuseoccurredmorefrequentlyinmenwithhighrisk
sexual behaviors (Table 3). Those reporting 10 or more
partners had almost triple adjusted odds of nPEP use (aOR:
2.9,[95%CI:1.9,4.4])relativetothosereportingzeroorone.
Signiﬁcantly increased odds of nPEP use were also seen for
men reporting 2–5 and 6–9 partners. Odds of nPEP use
increased stepwise with the HIV transmission risk of the
reported sexual behaviors: highest odds of nPEP use were
found with highest risk behaviors (URA with HIV?,
OR = 6.8 [95%CI: 5.0, 9.2], UIA with HIV? OR = 3.6
[95%CI: 2.7, 4.9]); increased odds of nPEP were found with
partners of unknown HIV status (URA with HIV-unk,
OR = 3.5 [95%CI: 2.7, 4.5]; UIA with HIV-unk, OR = 1.4
[95%CI: 1.0, 1.8]). We did not ﬁnd increased odds of nPEP
with unprotected sex with HIV uninfected partners: indeed
the trend was for decreased likelihood of nPEP use.
In a multivariable model including all sexual risk
behaviors, the highest transmission risk behaviors, URA
with HIV?, UIA with HIV? and URA with HIV-unk had
statistically signiﬁcant higher odds of nPEP use, and those
who reported in more than 5 partners were also more likely
Table 1 Baseline and follow-
up nPEP use and participant
demographics
Ever used nPEP prior to study Ever used nPEP during study
Overall
81/4289 1.9% 256/3819 6.7%
Site
Boston 15/728 2.1% 49/650 7.5%
Chicago 4/624 0.6% 30/527 5.7%
Denver 3/726 0.4% 20/683 2.9%
NYBC 11/734 1.5% 41/657 6.2%
San Francisco 37/734 5.0% 76/607 12.5%
Seattle 11/743 1.5% 40/675 5.8%
Race/Ethnicity
White, not Hispanic 60/3110 1.9% 176/2792 6.3%
Black, not Hispanic 5/281 1.8% 26/243 10.7%
Hispanic 9/648 1.4% 41/566 7.2%
Other 7/249 1.8% 13/212 6.1%
Age
16–19 1/93 1.1% 5/71 7.0%
20–25 6/720 0.8% 39/617 6.3%
26–30 12/911 1.3% 49/811 6.0%
31–35 26/909 2.9% 58/825 7.0%
36–40 12/754 1.6% 39/675 5.8%
[40 24/902 2.7% 66/820 8.0%
Education
High School/GED 5/406 1.2% 24/330 7.3%
Some College 19/1128 1.7% 55/986 5.6%
College Degree 32/1855 1.7% 109/1669 6.5%
Graduate/Professional 25/898 2.8% 68/833 8.2%
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behaviors: UIA with HIV- and UIA with HIV-unk were
markedly less likely to report nPEP use, after adjustment
for all other risk behaviors, with adjusted odds ratios of
0.58 [95%CI: 0.42, 0.81] and 0.69 [95%CI: 0.54, 0.98],
respectively.
Perception of Disinhibition and nPEP Use
The perception that nPEP would increase HIV risk
behaviors differed between those who had versus hadn’t
previously used nPEP at baseline: 60% of prior nPEP users
disagreed that availability of nPEP would increase unsafe
sex, 58% of those never using nPEP agreed with this
statement (v
2 = 10.0, P = 0.002). We examined whether
perceptions of nPEP and risk changed as a result of nPEP
use: amongst the 231 ﬁrst time users of nPEP during
EXPLORE, we found the mean perception of disinihibition
score before nPEP use was 3.32 but after was 2.64, indi-
cating a signiﬁcant shift toward disagreeing with the per-
ception that nPEP use increased high risk. behavior (paired
t-test = 7.7, P\0.001).
Table 2 Non-occupational Post
Exposure Prophylaxis use and
illicit drug and alcohol use
a All analyses adjusted for site,
study visit, race/ethnicity and
education
b All analyses include only
follow-up data, baseline
proportions given for reference
Behavior (last 6 months) Proportion
(Baseline)
b
aOR
a (95% CI) P-value
Any non-injection drugs 64.7% 1.50 (1.13, 1.99) 0.005
Injection drugs 10.2% 2.44 (1.69,3.51) \0.001
Non injection use of:
Marijuana 46.3% 1.22 (0.95,1.58) 0.120
Poppers 36.6% 1.48 (1.15,1.91) 0.002
Crack cocaine 4.2% 1.88 (1.15,3.09) 0.012
Cocaine(snorted or sniffed) 19.3% 1.27 (0.93,1.75) 0.129
Amphetamines 12.9% 2.32 (1.74,3.10) \0.001
Hallucinogens 24.0% 1.47 (1.11,1.94) 0.007
Alcohol
None 10.5% 1.00 –
Light 46.9% 0.89 (0.62,1.27) 0.51
Moderate 32.1% 0.93 (0.63,1.39) 0.74
Heavy 10.6% 1.09 (0.62,1.89) 0.77
Table 3 Non-occupational Post Exposure Prophylaxis Use during follow-up and HIV sexual risk behaviors
Behavior in last 6 months Proportion in
category (Baseline)
b
Univariate Models
a Multivariable model
a
OR 95% CI P-value aOR 95% CI P-value
URA with HIV- 32.1% 1.28 (0.99,1.66) 0.062 1.27 (0.91,1.77) 0.156
UIA with HIV- 32.9% 0.77 (0.58,1.01) 0.058 0.59 (0.42,0.83) 0.002
URA with HIV-unk 25.1% 3.47 (2.68,4.48) \0.001 2.67 (1.90,3.75) \0.001
UIA with HIV-unk 31.7% 1.36 (1.04,1.77) 0.023 0.69 (0.49,0.98) 0.037
URA with HIV? 5.9% 6.79 (5.01,9.19) \0.001 3.37 (2.13,5.31) \0.001
UIA with HIV? 10.5% 3.63 (2.67,4.94) \0.001 1.87 (1.19,2.85) 0.007
Number of male sex partners
0–1 7.2% 1.00 - 1.00 -
2–5 32.5% 1.66 (1.07,2.57) 0.02 1.44 (0.93,2.27) 0.10
6–9 23.0% 2.29 (1.45,3.60) \0.001 1.75 (1.11,2.76) 0.016
10? 37.3% 2.91 (1.91,4.44) \0.001 1.77 (1.27,2.78) 0.013
URA = any unprotected receptive anal sex, UIA = any unprotected insertive anal sex
HIV-=HIV uninfected partner, HIV-unk = partner of unknown HIV status, HIV?=HIV infected partner
a All analyses adjusted for site, race/ethnicity, education and study visit
b All analyses include only follow-up data, baseline proportions given for reference
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Use and HIV Risk Behaviors
We examined whether willingness to use nPEP use aligned
with actual nPEP use. Those ‘‘very likely’’ to use nPEP
following a known high risk exposure at baseline also had
higher odds of reporting subsequent nPEP use:
aOR = 3.08 [95%CI 2.25, 4.20, P\0.001] compared to
those who had said ‘‘somewhat’’ or ‘‘not very likely’’. We
also found those ‘‘very likely’’ to use nPEP had signiﬁ-
cantly lower odds of subsequently reporting SDUA (aOR:
0.59 [95%CI: 0.54, 0.65], Table 4).
High risk sexual behavior was more likely in those who
had previously reported nPEP. In men who used nPEP at
the prior visit, there were elevated odds of reporting SDUA
compared to those who didn’t previously use nPEP (aOR:
1.6, [95%CI: 1.2, 2.1], Table 4). However, when the
comparison is restricted to prior participant visits that were
potentially eligible for nPEP, i.e. visits where SDUA was
reported, the adjusted odds of SDUA was 0.76 [95%CI:
0.54, 1.06] in those who had used nPEP compared to those
who had not.
Discussion
Previous studies in San Francisco [17] and amongst vac-
cine study participants [14] have reported low use of nPEP
in the community setting. In the context of pro-active
provision of nPEP in 4-day take-home supply kits in a
Brazilian study [15], uptake was sharply increased, with
34% of men reporting beginning a course of PEP following
a high risk exposure. Uptake of nPEP at baseline in
EXPLORE is consistent with other cross-sectional studies
in the US, with only a small fraction of men reporting use
of antiretrovirals after a high risk exposure. In the
EXPLORE cohort somewhat higher reporting is seen dur-
ing follow-up, possibly as a result of increased contact with
the site during study participation. Increased knowledge
and perceived access as well as increased nPEP use was
seen in sites with active nPEP programs, suggesting that
exposure to nPEP information are factors that could
inﬂuence increased uptake of this prevention strategy,
however the use of nPEP in this high risk cohort is still
low. Unlike Liu [15], we found no patterns of association
with education.
Knowledge of nPEP was perhaps surprisingly low given
the wide spread use of treatment for HIV/AIDS in these
cities, with less than half the cohort aware of this use of
antiretroviral drugs, and only 40% in sites without active
nPEP programs. Much of the knowledge seems to have
been propagated through health care providers and word of
mouth; clearly newspapers and advertising were effective
in increasing awareness in the nPEP sites. Interestingly, in
a subsequent study at the same Boston site, Mayer [13]
found even lower knowledge of pre-exposure prophylaxis
(PrEP), with 81% of Boston MSM having not heard about
PrEP. In that group, concerns about antiretroviral side
effects and behavioral disinhibition were ameliorated with
information about side effects and cautions against risk
compensation. The increased utilization of nPEP during the
EXPLORE study at the San Francisco and Boston sites
would suggest that local programs can result in enhanced
utilization.
NPEP was not associated with any suggestion of change
in seroconversion risk in this cohort, though low rates of
nPEP use gave little power to detect an association. NPEP
use in this cohort clearly reﬂected the CDC guidelines in
place: nPEP use was most strongly associated with the
highest risk HIV behaviors with partners known to be HIV-
infected or whose status is unknown. The ﬁnding in the
multivariable analysis that nPEP is signiﬁcantly less likely
to be used with unprotected insertive sex with HIV unin-
fected partners or partners of unknown status possibly
reﬂects a subgroup who exclusively practiced risky inser-
tive sex and did not use nPEP because they did not consider
themselves at risk. As also reported in other studies,
increased uptake of nPEP is found amongst those who use
illicit drugs, and those who inject drugs, while alcohol use
has no association with nPEP use.
Perception about nPEP use and behavioral disinhibition
differed depending on whether the participant had
Table 4 Serodiscordant unprotected sex (SDUA) and association with willingness to use and previous use of non-occupational Post Exposure
Prophylaxis
nPEP behaviors N Any SDUA P-value
aOR
a (95% CI)
Willingness to use nPEP: Very likely vs. somewhat/not likely to use nPEP after high risk sex 4091 0.59 (0.54, 0.65) \0.001
nPEP use vs. no nPEP use at previous visit 4091 1.62 (1.23, 2.13) 0.001
nPEP use vs. no nPEP use at previous visit, in men reporting SDUA at previous visit. 2898 0.76 (0.54, 1.06) 0.11
SDUA—unprotected anal sex with an HIV infected or unknown HIV status partner
a All analyses adjusted for site, race/ethnicity, education and study visit
AIDS Behav (2010) 14:1182–1189 1187
123previously used nPEP. For those who had used nPEP prior
to the study, the majority did not think the availability of
nPEP after high risk exposures would increase the likeli-
hood of unsafe sex. In those who had never used nPEP, the
majority view was opposite. Similarly, amongst those using
nPEP for the ﬁrst time during study follow-up the per-
ception that nPEP would increase unsafe sex changes from
the ‘‘agreement’’ to ‘‘disagreement’’ range following ﬁrst
nPEP use. The difference in perception seems likely to
simply reﬂect changes in attitudes following actual expe-
rience of nPEP—those who have never used nPEP are
answering a hypothetical question, whereas those who have
used nPEP can answer based on their own experience.
Decreased risk was reported after nPEP use in a San
Francisco cohort—a report that is consistent with nPEP
user’s perceptions in our study. Dissonance between
hypothetical questions and actual behavior is seen in other
situations, for example, in hypothetical vs. actual willing-
ness to be in a vaccine trial [27].
MSM who knew about nPEP and stated they would very
likely use nPEP after a known exposure were more likely
to use nPEP, demonstrating consistency between knowl-
edge, willingness and actions. However willingness to use
nPEP was not an indicator of greater risk, indeed we found
willingness was associated with 40% lower odds of SDUA.
Increased knowledge about nPEP and its availability as a
prevention strategy did not lead to increased risk in this
cohort.
None-the-less, nPEP use does appear to characterize a
group with higher HIV risk behaviors. A unique strength of
this study is the longitudinal prospective assessment of
nPEP where we can assess the effect of nPEP use on
subsequent behavior. We found users of nPEP remained a
high risk group compared to the cohort as a whole,
reporting higher SDUA at subsequent visits. However
nPEP use did not appear to lead to increased sexual risk
amongst men who reported risk behaviors that would make
them eligible for nPEP. Reduction in risk was similarly
found after use of nPEP in a prospective study of MSM in
San Francisco [18]. This supports other similar reports that
nPEP use did not lead to increased risk behavior, but also
points to the need for access to repeated nPEP use amongst
MSM with the highest exposure risk.
This study only reports attitudes and use of nPEP within
a high risk cohort in large urban centers with large MSM
populations. The low rate of nPEP use and small number of
seroconversions observed gives low power to determine
whether nPEP was effective in preventing infection. Risk
behaviors and nPEP use were self-reported for the previous
6 month period, and it was not possible to assess whether
nPEP use followed or preceded high risk behavior.
This study provides strong evidence that the CDC
guidelines for nPEP use were being followed within this
cohort of high risk men who have sex with men, although
uptake was not high. The perception in the non-nPEP users
that unsafe sex is made more likely with availability of
nPEP points to a negative perception of nPEP as a pre-
vention strategy, potentially a factor associated with its
non-use. Our ﬁndings suggest that nPEP was not perceived
as an alternative to safe sex, nor that the experience of
accessing and taking nPEP increased risky sexual behavior.
However, within the subset of people who had reported sex
behaviors where nPEP use was recommended, previous
nPEP use was not associated with higher odds of high risk
sex, thus allaying fears that availability of nPEP would lead
to an increase in high risk sex.
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